Zhang Xinhe, Guan Lin, Tian Haoyu, Zeng Zilu, Chen Jiayu, Huang Die, Sun Ji, Guo Jiaqi, Cui Huipeng, Li Yiling
Gastroenterology Department, The First Affiliated Hospital of China Medical University, Shenyang, China.
The 3rd Clinical Department of China Medical University, Shenyang, China.
Front Oncol. 2021 Sep 9;11:686962. doi: 10.3389/fonc.2021.686962. eCollection 2021.
Hepatocellular carcinoma (HCC) is a common cancer in the world, and its incidence is increasing yearly. Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection are important causes of HCC. Liver cirrhosis, age, sex, smoking and drinking, and metabolic risk factors will increase the risk of cancer in HBV/HCV patients. And viral load, APRI, FIB-4, and liver stiffness can all predict the risk of HCC in patients with viral infection. In addition, effective prevention strategies are essential in reducing the risk of HCC. The prevention of HCC involves mainly tertiary prevention strategies, while the primary prevention is based on standardized vaccine injections to prevent the occurrence of HBV/HCV. Eliminating the route of transmission and vaccination will lead to a decrease in the incidence of HCC. Secondary prevention involves effective antiviral treatment of HBV/HCV to prevent the disease from progressing to HCC, and tertiary prevention is actively treating HCC to prevent its recurrence.
肝细胞癌(HCC)是全球常见的癌症,其发病率逐年上升。乙型肝炎病毒(HBV)感染和丙型肝炎病毒(HCV)感染是HCC的重要病因。肝硬化、年龄、性别、吸烟饮酒以及代谢风险因素会增加HBV/HCV患者的患癌风险。病毒载量、APRI、FIB-4以及肝脏硬度均能预测病毒感染患者发生HCC的风险。此外,有效的预防策略对于降低HCC风险至关重要。HCC的预防主要涉及三级预防策略,而一级预防基于标准疫苗接种以预防HBV/HCV的发生。消除传播途径和接种疫苗将导致HCC发病率下降。二级预防包括对HBV/HCV进行有效的抗病毒治疗以防止疾病进展为HCC,三级预防则是积极治疗HCC以防止其复发。